Is FHIR R5 Ready for Production, and How Can R4 and R5 Systems Work Together in 2026?

Short Answer: Treat FHIR R5 as a Migration Target, Not a Default Operating Standard

Yes, FHIR R5 organizations can coexist with systems that implement FHIR R4, but compatibility is not automatic. A system claiming “FHIR R5 compatibility” should not be expected to communicate correctly with every R4 endpoint simply because both versions use the same resource names. The practical answer as of September 26, 2026 is to support FHIR R4 as the production baseline where partner maturity demands it, model data in a version-aware way, and add R5 support only through tested adapters, profiles, and negotiated capabilities. R5 offers newer resources, clearer maturity distinctions, and improvements in areas such as terminology, subscriptions, and workflow definitions, yet its adoption varies by vendor, country, regulatory program, and implementation guide.

Also worth reading: Is AI Prior Authorization Automation Ready for Clinics in 2026, and How Should Health Systems Adopt It? · What Are FHIR Validation Best Practices for Clinical Systems? · How Should a FHIR R5 Vital Signs Mapping Work for Clinic Data Integration?

For a care-coordination and patient-pulse platform, compatibility should mean that authorized clinical teams can exchange the required observations, conditions, medications, care plans, referrals, and patient signals without corrupting meaning or losing provenance. It does not mean that the product must expose every R5 element, accept every R5 code system, or pass every conformance test in every jurisdiction. The best architecture usually maintains a stable internal contract and translates it at integration boundaries. Vendors that jump directly from R4 to R5 without profiling or regression testing create more risk than they remove.

What Changed Between FHIR R4 and FHIR R5?

FHIR R4 is based on version 4.0.1 and remains one of the most widely deployed clinical interoperability versions. It established a mature collection of resources and made JSON and XML widely available for exchange. FHIR R5 is a later specification release with a larger and reorganized resource set. It also refines maturity classifications, expands terminology support, introduces or improves resources, and changes some cardinalities, value sets, bindings, invariants, and workflow mechanisms. Because the changes are not confined to newly introduced resources, treating R5 as a cosmetic upgrade can produce silent interoperability failures.

Compatibility depends on the exact resource, profile, extension, code system, and operation being used. A client may read Observation, Patient, and Encounter successfully in both versions while failing on a mandatory R5 element or an R4 profile. Terminology can differ even when human-readable labels appear identical. Extensions may also be renamed, constrained, or represented differently. Consequently, a successful connection test proves very little; each clinical use case needs validation against the server’s declared CapabilityStatement and the applicable implementation guide.

FHIR R4B exists between these releases and matters when deciding what “current FHIR” means. It is not identical to either R4 or R5 and can be a better fit for organizations participating in specific extension or international implementation programs. A system should not accept the vague statement that it handles “FHIR 4 and 5” without identifying minor versions, national profiles, supported resources, and tested operations. The more precise the compatibility claim, the easier buyers and implementation partners can assess it.

## Why R4 and R5 Compatibility Requires More Than Two API Endpoints

A FHIR server does not become R5-compatible merely by accepting requests on another port. A correct implementation needs version-aware resource definitions, terminology services, search behavior, pagination, authorization, conformance metadata, and error handling. The server should publish a CapabilityStatement that accurately states which version, resources, profiles, interactions, and parameters it supports. Clients should read that metadata instead of assuming that the presence of a resource type guarantees complete support.

The largest risk is semantic drift. For example, a patient-pulse service may consume a score such as a blood-pressure measurement or a validated questionnaire response from R4, then represent it through an R5-oriented internal model. If it changes the profile, units, reference semantics, provenance, or terminology binding without an explicit rule, downstream systems may interpret the same value differently. Translation must preserve units, codes, effective time, source, author, consent context, and the identity of the source record wherever those fields remain valid.

Extensions create another common source of error. Clinical vendors often add information that is not represented cleanly by standard base fields. An R4 extension cannot simply be copied into R5 if its definition has changed or if the receiving system expects a different cardinality. The adapter should maintain an extension registry, document when an item cannot be represented, and avoid silently dropping data. A measured migration should identify whether all outbound fields are preserved, intentionally transformed, stored for later processing, or rejected with a clear error.

A Practical Migration Architecture for Care Networks

The most dependable design uses a canonical internal data layer rather than forcing one FHIR version onto every partner. R4, R4B, and R5 payloads should be parsed at separate integration boundaries, validated against the expected profile, normalized into a documented internal representation, and translated into the target version when leaving the platform. This approach reduces repeated business logic and makes unsupported combinations visible. It also allows a clinic still operating R4 to share selected patient-pulse data with a network whose newer service operates R5.

The flow should include five controls. First, discovery should retrieve the remote CapabilityStatement and record the declared version. Second, validation should apply the relevant profiles, terminology bindings, cardinalities, and invariants. Third, normalization should preserve coded values, units, references, effective dates, and provenance. Fourth, transformation should use a deterministic field-level mapping rather than a generic JSON copier. Fifth, verification should validate the outbound payload and perform round-trip tests against representative records.

A translation policy must also decide what happens to information with no safe target. Common choices include retaining the original payload, using an approved extension, placing the item in a documented local store, omitting it with an audit record, or failing the transaction. Silent omission is the least acceptable option. For B2B integrations, the platform should expose which profiles and fields are supported by each tenant, because two customers connecting to the same product may use different national profiles and FHIR versions.

Useful test cases should cover the ordinary path and several traps. Test equal codes with different systems, changed value sets, missing optional elements, mandatory elements added by a profile, deleted or renamed fields, references to different resource types, and profiles that constrain a resource more tightly than the base specification. For operational testing, include pagination across at least 1,000 resources, conditional search behavior, bundle processing, retry handling, expired tokens, and duplicate submissions. Ten happy-path test records are not enough evidence of compatibility.

A Staged Implementation Plan for 2026

Start with a partner inventory rather than a version decision. Classify each EHR, health information exchange, payer, device vendor, laboratory, and referral partner by the exact FHIR version, implementation guide, national profile, and required operations. Give systems categories such as R4 core, R4 national profile, R4 extensions, R4B, R5, unknown, and non-FHIR. Record not only the advertised version but also evidence from a CapabilityStatement or a successful validation run.

Next, define the minimum exchange set. A patient-pulse use case may require fewer resources than a full clinical platform: Patient, Practitioner, Organization, Observation, Condition, MedicationRequest, CarePlan, ServiceRequest, Questionnaire, and QuestionnaireResponse may be central, while Provenance and AuditEvent support trust and oversight. The first release should not claim every resource in R5. Select the 10 to 20 most valuable interactions, document supported search parameters, and establish acceptance thresholds such as 99.9% successful payload validation on the test set and zero known loss of clinically required fields.

Build the R4 path first if it serves the largest installed base, then add an R5 adapter without changing the core workflow. Run the same business-level test suite against both. A proposed threshold of at least 95% automated interoperability coverage can be a starting target, but manually reviewed high-risk scenarios should supplement code coverage. Pilot with at least 2 organizations using different profiles or EHR products, operate in parallel for 30 to 90 days, and compare discrepancies before expanding. This sequence produces evidence instead of relying on roadmap language.

A release should be rejected if metadata misidentifies supported capabilities, a translation loses a required clinical value, or authorization behavior changes between versions. Version-specific dashboards should show request counts, validation failures, unknown codes, dropped fields, latency, and partner-specific errors. If the pilot produces unresolved semantic conflicts, narrow the advertised scope rather than presenting the integration as broadly compatible.

Comparison of R4-First, Dual-Version, and R5-First Options

An R4-first strategy is usually appropriate for health systems and clinic networks with a broad R4 installed base. It reduces initial implementation effort and aligns with many existing implementation guides. Its weakness is that native R5 adopters may need an external translation service, and the organization can accumulate vendor extensions that become expensive to maintain. This approach works best when the product is primarily connecting with established EHRs and when national or payer specifications still specify R4.

A dual-version platform offers the best balance for many multi-tenant care networks. It allows each tenant to negotiate an appropriate version through metadata and keeps version-specific parsing outside the product’s core services. The cost is ongoing testing, documentation, support, and monitoring for every supported combination. Dual version does not necessarily require maintaining two complete clinical databases; the same internal model can support both boundaries. However, an adapter cannot repair information that was never captured or cannot be safely translated.

An R5-first strategy is defensible for a greenfield deployment with confirmed R5 partners, strong implementation-guide support, and internal expertise in R5 profiles and terminology. It may reduce long-term work if the partner ecosystem is known to be moving in one direction. It is a poor default for a general clinic product whose buyers still rely heavily on R4. A vendor claiming R5 readiness should provide a tested capability matrix, sample R5 payloads, validation results, and references from real integrations.

## Common Mistakes That Make “R5 Support” Misleading

The first mistake is equating the specification version with implementation compliance. Passing base R5 validation does not prove support for a country-specific profile, a payer API, or an EHR vendor’s extensions. The second is translating by field name alone. A field may have the same JSON name but a different meaning, binding, or cardinality in another version. The third is testing only newly created data; imported, corrected, deleted, and historical records often expose stricter constraints.

Another mistake is ignoring server operations. Creating resources is only one part of interoperability. Search, read, update, patch, history, transaction processing, and conditional creation can behave differently across profiles. Some partners need _lastUpdated, _profile, code filters, date ranges, or custom search parameters. Bulk synchronization may also require handling HTTP 429 responses, pagination links, malformed bundles, and partial transaction failures.

Terminology deserves explicit testing. A code can be valid in one release or value set but absent in another. Automatic system substitution based on a matching display label is unsafe because labels are not permanent identifiers. Use the code, system, and version, then consult the terminology service or mapping rules. When a clinically important concept has no approved mapping, escalate the case rather than assigning a nearby code.

Finally, do not hide unsupported mappings behind marketing language. A capability page should report exact versions, resource coverage, profiles, operations, terminology servers, and known limitations. Customers should be able to distinguish native support from conversion, partial support, and unsupported use. This clarity is especially important where incorrect patient data can affect care coordination, outreach, or reporting.

Cost, Timing, and When to Act Now

Exact FHIR integration pricing varies too much for a responsible universal figure. A narrow R4 client connection using a hosted test server may cost little beyond configuration and testing, while production integration, profile development, terminology licensing, security review, and operational support can run from tens of thousands to hundreds of thousands of dollars. A broad dual-version network program may exceed that range. Vendors may charge separately for interface engines, conformance testing, mapping development, tenant onboarding, support tiers, and national-profile packages, so buyers should request a line-item statement rather than a per-resource price alone.

A focused R4-to-R5 pilot for one or two workflows might take 8 to 16 weeks when partners already provide stable test environments. A production rollout across several EHR products, additional profiles, identity reconciliation, consent controls, and operational monitoring commonly takes 4 to 9 months. These are planning ranges, not guarantees. A partner lacking a reliable CapabilityStatement, stable terminology, or test data can extend the schedule substantially.

For a care network, action is warranted now if R5 represents more than 10% to 20% of planned or active integration demand, if a strategic partner requires it, or if the platform’s data model makes later mapping unusually risky. Waiting may be sensible when nearly all partners are standardized on R4, no authoritative implementation guide is available for the required workflow, or the product has no ability to validate profiles and terminology. The decision should be based on partner evidence and a 12- to 24-month roadmap rather than on FHIR’s release number alone.

The prudent September 26, 2026 position is to advertise tested R4 support, maintain a controlled R5 pathway, and avoid claiming blanket bidirectional compatibility. For getpulse.care, R5 can support richer care-coordination workflows when it improves real exchange, but it should earn its place through measurable coverage, accurate semantics, and lower operational risk rather than specification prestige.